OrthoPediatrics Corp's Q3 prelim revenue up 12%

Orthopediatrics

09/10/2025 21:21

Overview

OrthoPediatrics Q3 prelim revenue grows 12% yr/yr to $61.2 mln, missing analyst expectations

Company revises 2025 revenue guidance due to delayed 7D capital sales

OrthoPediatrics faces headwinds in Latin and South America, impacting revenue

Outlook

OrthoPediatrics lowers 2025 revenue guidance to $233.5 mln-$234.5 mln

Company maintains 2025 adjusted EBITDA guidance at $15 mln-$17 mln

OrthoPediatrics sees minimal sales growth from Latin and South America

Result Drivers

DELAYED SALES - Delayed 7D capital sales and timing of set sales in Latin and South America impacted revenue growth

INTERNATIONAL CHALLENGES - Prelim international revenue grew 6% yr/yr, affected by timing of set sales and large stocking orders

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$61.20 mln
$63.60 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $35.00, about 48.3% above its October 8 closing price of $18.10

Press Release: ID:nGNX68xtj7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)